Atlas Trials

A Phase 1 Study to Evaluate the Safety, Tolerability, and Immunogenicity of UB-313 in Healthy Participants

Clinical trial NCT05477095 · COMPLETED

Trial details

NCT number
NCT05477095
Sponsor
Vaxxinity, Inc.
Status
COMPLETED
Phase
Phase 1
Study type
INTERVENTIONAL
Migraine
Start date
2022-07-06
Primary completion
2023-10-06
Enrollment
40

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.